1 week Ago By ABMN Staff
Geode Capital Management LLC lifted its stake in Summit Therapeutics Inc. ( NASDAQ:SMMT – Free Report ) by 3.3% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission.
The fund owned 3,200,847 shares of the company’s stock after buying an additional 101,039 shares during the quarter. Geode Capital Management LLC’s holdings in Summit Therapeutics were worth $57,133,000 as of its most recent SEC filing. Other hedge funds and other institutional investors have also recently bought and sold shares of the company.
Vanguard Group Inc. boosted its position in Summit Therapeutics by 6.6% in the 4th quarter.
Vanguard Group Inc. now owns 11,670,576 shares of the company’s stock worth $208,261,000 after purchasing an additional 724,040 shares in the last quarter. Pictet Asset Management Holding SA boosted its holdings in Summit Therapeutics by 100.
6% during the fourth quarter. Pictet Asset Management Holding SA now owns 1,387,247 shares of the company’s stock worth $24,755,000 after buying an additional 695,843 shares in the last quarter. IvyRock Asset Management HK Ltd acquired a new stake in Summit Therapeutics during the fourth quarter valued at $2,972,000.
abrdn plc increased its holdings in Summit Therapeutics by 13.6% in the fourth quarter. abrdn plc now owns 1,290,425 shares of the company’s stock valued at $23,028,000 after buying an additional 154,139 shares in the last quarter.
Finally, Principal Financial Group Inc. raised its position in shares of Summit Therapeutics by 252.8% in the fourth quarter.
Principal Financial Group Inc. now owns 205,150 shares of the company’s stock worth $3,661,000 after acquiring an additional 147,003 shares during the period. 4.
61% of the stock is owned by institutional investors and hedge funds. Summit Therapeutics Trading Up 15.3 % Shares of NASDAQ SMMT opened at $23.
24 on Monday. The stock has a market cap of $17.14 billion, a PE ratio of -83.
00 and a beta of -0.46. Summit Therapeutics Inc.
has a 12-month low of $2.10 and a 12-month high of $33.89.
The company has a 50-day moving average of $19.70 and a 200 day moving average of $19.64.
Analyst Upgrades and Downgrades Several brokerages recently weighed in on SMMT. Citigroup upgraded Summit Therapeutics from a “neutral” rating to a “buy” rating and lifted their price target for the company from $23.00 to $35.
00 in a research note on Wednesday, March 26th. Summit Redstone set a $35.00 target price on Summit Therapeutics in a research note on Wednesday, March 26th.
StockNews.com raised shares of Summit Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, March 5th. The Goldman Sachs Group initiated coverage on shares of Summit Therapeutics in a research report on Friday, February 28th.
They set a “buy” rating and a $42.00 price objective for the company. Finally, Truist Financial started coverage on shares of Summit Therapeutics in a research report on Wednesday, January 8th.
They issued a “buy” rating and a $35.00 target price on the stock. One investment analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock.
Based on data from MarketBeat, Summit Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $35.40. Read Our Latest Analysis on Summit Therapeutics Summit Therapeutics Company Profile ( Free Report ) Summit Therapeutics Inc, a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom.
The company’s lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. Recommended Stories Want to see what other hedge funds are holding SMMT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Summit Therapeutics Inc.
( NASDAQ:SMMT – Free Report ). Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
